Oral Transmucosal Drugs Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global Oral Transmucosal Drugs Market Is Segmented By Product Type (Tablets, Films, Liquids & Spray, Others), By Indication(Neurological Disorders, Opioid Dependence, Nausea and Vomiting, Erectile Dysfunction, Neurological Disorders), By Route of Administration(Sublingual Mucosa, Buccal Mucosa, Others), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
 

Oral Transmucosal Drugs Market Size

The global oral transmucosal drugs market reached USD 15,005.2 million in 2022 and is projected to witness lucrative growth by reaching up to USD 24,441.4 million by 2030. The market is expected to exhibit a CAGR of 6.4% during the forecast period (2023-2030).

Oraltransmucosal drug administration was an alternative route in end-of-life care and palliative care during the COVID-19 pandemic. Oral transmucosal drug delivery is the systemic distribution of drugs through the mucous membrane of the oral cavity. It is a preferred approach in palliative care compared to other transmucosal drug delivery since it is practical and easy to use. Oral transmucosal drug delivery is a different method for delivering dose formulations for oral or nasal administration. 

The increase in incidence of autoimmune disorders, cancer cases, and respiratory issues, technological advancements, and the rise in research activities by the key players about novel oral transmucosal drugs drive the global oral transmucosal drugs market growth.

Oral Transmucosal Drugs Market Scope

To Know More Insights - Download Sample

Oral Transmucosal Drugs Market Dynamics

Increase in the incidence of autoimmune disorders and, cancer to boost the market growth.

Due to the rise in autoimmune illnesses and cancer, the global market for oral transmucosal drugs is likely to grow during the forecast period. Oral cancer and autoimmune illnesses are all diseases that are affecting more and more people worldwide. This increases demand for oral transmucosal medications as they can prevent gastrointestinal degradation and have an immediate start of action.

For instance, according to the CDC's National Diabetes Statistics Report, there are expected to be 37.3 million cases of diabetes worldwide in 2022. About 11.3% of Americans, or 37.3 million people, have diabetes. The 28.5% of the population, or an estimated 28.7 million people, had diabetes, due to which, the demand for transmucosal medications also increases.

Regulatory challenges for the transmucosal drugwill hamperthe globaloral transmucosal drugs marketgrowth.

Regulatory challenges are one of the major factors that can impact the development and commercialization of transmucosal drugs. Some of the regulatory challenges faced by transmucosal drugs include: like all pharmaceutical products, transmucosal drugs must undergo rigorous safety and efficacy testing to gain regulatory approval. 

Oral Transmucosal Drugs Market Segment Analysis

The global oral transmucosal drugs market is segmented based on product type, indication, route of administration, distributionchannel and region.

The tablets segment is expected to hold a dominant position in the market over the forecast period.

Tablets segment accounted for the highest market stake, accounting for approximately 47% of the oral transmucosal drugs market share in 2022, owing to the benefits provided by oral transmucosal tablets are including quick absorption, the convenience of administration, less interaction with other medications, and the factors mentioned above helps tablets segment is likely to hold a significant share of the market. For instance, according to a study published in the National Library of Medicine's Journal in August 2021, older adults who take multiple medications frequently experience a decrease in salivary output. The study also revealed that dental risks for older adults who have low resting pH and low stimulated salivary flow rates increase by 63%. 

Source: DataM Intelligence Analysis (2023)

Oral Transmucosal Drugs Market Geographical Share

North America holds a dominant position in the global oral transmucosal drugs market.

North America is estimated to hold about 37% of the totaloral transmucosal drugs market share overthe forecast period.The active regional players and availability of drugs and opioid use disorders helpdrive the market growth in North America. For instance, as per the article published in Stat Pearls in 2022, in the U.S. and throughout the world, opioid use disorder and addiction are still at pandemic levels. 

Opioid use disorder (OUD) has affected 3 million American residents and 16 million other people, worldwide. In the U.S., heroin dependence affects more than 500,000 people. The demand for the prescription of opioid drugs is unquenchable in the U.S. 

Source: DataM Intelligence Analysis (2023)

Oral Transmucosal Drugs Market Companies 

The major global players in the market include Pfizer Inc., ZIM Laboratories Limited, Aquestive Therapeutics, Inc, IntelGenx Corp, Indivior PLC, C.L.Pharm Co., Ltd, Seoul Pharmaceuticals, Shilpa Therapeutics, Sunovion Pharmaceuticals, Inc, and CURE Pharmaceutical, among others.

Russia Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a minimal impact on the global oral transmucosal drugs market, owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global oral transmucosal drugs market over the forecast period.

Artificial Intelligence Impact Analysis

Artificial intelligence is expecetd to impact positively for the global oral transmucosal drugsmarket. Artificial neural networks (ANNs), information technology, and wireless communication all play a role in the development of smart medication delivery systems that have the potential to overcome the drawbacks of traditional therapeutic approaches. Devices for regulated drug distribution have more versatility because of the wireless connection.

Key Developments

• On May 21, 2022, ZIM Laboratories Limited announced that AEPMS, the Spanish Agency for Medicine and Healthcare Products, granted marketing authorization to its fully owned European subsidiary, SIA ZIM Laboratories Limited, for its novel product, "Sildenafil 50 mg" ODS, in Spain.
• On December 22, 2022, Aquestive Therapeutics, Inc.'s End-of-Phase 2 (EOP2) meeting with the US Food and Drug Administration ("FDA") for AQST-109 was announced by the company
• On September 28, 2022, Aquestive Therapeutics, Inc., a pharmaceutical company, announced that it entered into a license agreement of supply for Libervant (diazepam) Buccal Film.

Why Purchase the Report?

• To visualize the global oral transmucosal drugs market segmentation based on product type, Indication, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of oral transmucosal drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global oral transmucosal drugs market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies